Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Early Phase 1
1(33.3%)
N/A
1(33.3%)
3Total
Phase 1(1)
Early Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02959294Early Phase 1Withdrawn

Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries

Role: lead

NCT02961114Phase 1Withdrawn

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

Role: lead

NCT03297177Not ApplicableUnknown

Autologous Stem/Stromal Cells in Neurological Disorders and Disease

Role: collaborator

All 3 trials loaded